Valuation: Avalo Therapeutics, Inc.

Market Cap 965M 839M 783M 719M 1.36B 92.03B 1.38B 9.24B 3.62B 45.89B 3.63B 3.55B 151B P/E 2026 *
-7.39x
P/E 2027 * -6.1x
Enterprise Value 546M 475M 443M 407M 767M 52.05B 780M 5.22B 2.05B 25.96B 2.05B 2.01B 85.61B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.28%
Yield 2026 *
0.06%
Yield 2027 * -
1 day-1.10%
1 week-2.11%
Current month-1.10%
1 month-4.19%
3 months+31.66%
6 months+15.34%
Current year-0.61%
1 week 17.75
Extreme 17.75
19.97
1 month 17.54
Extreme 17.54
20.65
Current year 12.51
Extreme 12.51
24.27
1 year 7.87
Extreme 7.87
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap.
27/7/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
30/6/26 Free

Director

1,080 0.0020%
30/6/26 Fiscal year

Chief Technology Officer

13,962 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%-2.11%+128.77%-62.40% 965M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-10.22%+23.62%+58.59% 53.6B
+1.84%+3.27%-14.06%-12.13% 22.91B
-0.15%-7.92%-9.42%+352.23% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-1.73%+33.09%-31.09% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+3.83%-0.56%+47.77%+170.70% 13.33B
Average +0.93%-1.80%+47.82%+142.78% 23.48B
Weighted average by Cap. +0.14%-1.70%+32.11%+122.37%

Financials

2026 *2027 *
Net sales - -
Net income -85.72M -74.5M -69.55M -63.85M -120M -8.17B -122M -820M -321M -4.07B -322M -315M -13.44B -110M -95.96M -89.59M -82.25M -155M -10.52B -158M -1.06B -414M -5.25B -415M -406M -17.31B
Net Debt -419M -365M -340M -312M -589M -39.98B -599M -4.01B -1.57B -19.94B -1.58B -1.54B -65.75B -305M -265M -248M -227M -429M -29.09B -436M -2.92B -1.14B -14.5B -1.15B -1.12B -47.84B
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
04/08/26 US$18.05 -1.10% 545,458
31/07/26 US$18.25 -5.88% 923,877
30/07/26 US$19.39 +2.00% 935,221
29/07/26 US$19.01 -2.61% 789,787
28/07/26 US$19.52 +0.10% 815,719
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
18.25USD
Average target price
44.69USD
Spread / Average Target
+144.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock